Rebif

Rebif
Generic Name: interferon beta-1a (in ter FEAR on BAY ta)
Brand Names: Rebif
Company: Serono Laboratories
FDA Approved: March 2002
Rebif is rated 7.0/10

Rebif (interferon beta-1a) is made from human proteins. Interferons help the body fight viral infections.

Rebif is used to treat relapsing multiple sclerosis (MS) in adults.

Rebif will not cure MS, it will only decrease the frequency of relapse symptoms.

Rebif dosing information
Usual Adult Dose for Multiple Sclerosis:

22 mcg or 44 mcg subcutaneously 3 times a week:
TITRATION DOSE FOR 22 MCG:
Weeks 1 to 2: 4.4 mcg subcutaneously 3 times a week
Weeks 3 to 4: 11 mcg subcutaneously 3 times a week
Weeks 5+: 22 mcg subcutaneously 3 times a week
TITRATION DOSE FOR 44 MCG:
Weeks 1 to 2: 8.8 mcg subcutaneously 3 times a week
Weeks 3 to 4: 22 mcg subcutaneously 3 times a week
Weeks 5+: 44 mcg subcutaneously 3 times a week

Use: For the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

Important Information
Some people have thoughts about suicide while using Rebif. Stay alert to changes in your mood or symptoms. Report any new or worsening symptoms to your doctor.

Interferon beta-1a can harm your liver. Call your doctor if you have symptoms such as nausea, loss of appetite, tiredness, confusion, easy bruising or bleeding, dark urine, clay-colored stools, or yellowing of your skin or eyes.

Before using Rebif, tell your doctor if you are allergic to any drugs, or if you have liver disease, a thyroid disorder, epilepsy or other seizure disorder, heart disease, chest pain (angina), congestive heart failure, a heart rhythm disorder, or a history of depression or suicidal behavior.